Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1983 Jul;72(1):260–269. doi: 10.1172/JCI110965

Immunochemical analysis and immunogenicity of the type II group B streptococcal capsular polysaccharide.

D L Kasper, C J Baker, B Galdes, E Katzenellenbogen, H J Jennings
PMCID: PMC1129181  PMID: 6192144

Abstract

The relationship between group B streptococcal (GBS) type-specific antisera and the type II-specific polysaccharide is evaluated from a structural and immunologic viewpoint. Although all GBS type-specific polysaccharides are composed of the same monosaccharides, the type II antigen is more complex structurally and contains these sugars in a molar ratio different from the other antigens. Type II polysaccharide has two side chains. One contains only sialic acid and is less susceptible to acid cleavage than sialic acid residues found on types III, Ia, and Ib polysaccharides. The other side chain is composed of galactose as the only sugar. Immunochemical studies demonstrate that the type II polysaccharide has several immunodeterminants. One of these determinants is likely to be the side-chain galactose, while sialic acid appears to comprise part of another immunodeterminant, more complex than sialic acid alone. A series of cross-reactions is demonstrated between the type II native antigen and antisera to serotypes Ia, III, and Ib by a sensitive radioactive antigen-binding assay, which account for additional, complex immunodeterminants. The strongest of these cross-reactions is with type Ia antiserum and the weakest with Ib antiserum. Since Ia and Ib polysaccharides differ in only one linkage, these findings suggest that the trisaccharide beta D-N-acetyl-glucosamine-p(1 leads to 3) beta D-galactose-p(1 leads to 4) beta D-glucose-p [[beta D-GlcNAcp(1 leads to 3) beta D-Galp(1 leads to 4)beta D-Glcap]] is the likely common site responsible for the interaction of the type II native polysaccharide and type Ia antiserum. Another cross-reaction is observed between type III antiserum and type II native antigen. Inhibition studies indicate that the most likely cross-reactive determinant in this case is [beta D-Galp(1 leads to 4)beta D-GlcNAcp]. Type II polysaccharide has been utilized in a human vaccine trial to test safety and immunogenicity. The polysaccharide is highly immunogenic, inducing an antibody response in 95% of recipients, and nontoxic, with side-effects confined to minimal local reactions. Despite the cross-reactions observed between type-specific antigens and antibody prepared by immunization of rabbits with whole bacteria, which suggest shared immunodeterminants, similar cross-reactions were not detected in human sera after immunization with purified type II polysaccharide.

Full text

PDF

Images in this article

264FIGURE 2
on p.264
264FIGURE 3
on p.264

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker C. J., Edwards M. S., Kasper D. L. Immunogenicity of polysaccharides from type III, group B Streptococcus. J Clin Invest. 1978 Apr;61(4):1107–1110. doi: 10.1172/JCI109011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baker C. J. Group B streptococcal infections. Adv Intern Med. 1980;25:475–501. [PubMed] [Google Scholar]
  3. Baker C. J., Kasper D. L. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med. 1976 Apr 1;294(14):753–756. doi: 10.1056/NEJM197604012941404. [DOI] [PubMed] [Google Scholar]
  4. Baker C. J., Kasper D. L., Edwards M. S., Schiffman G. Influence of preimmunization antibody levels on the specificity of the immune response to related polysaccharide antigens. N Engl J Med. 1980 Jul 24;303(4):173–178. doi: 10.1056/NEJM198007243030401. [DOI] [PubMed] [Google Scholar]
  5. Baker C. J., Kasper D. L., Tager IRAB, Paredes A., Alpert S., McCormack W. M., Goroff D. Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus. J Clin Invest. 1977 May;59(5):810–818. doi: 10.1172/JCI108703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Baltimore R. S., Kasper D. L., Baker C. J., Goroff D. K. Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci. J Immunol. 1977 Feb;118(2):673–678. [PubMed] [Google Scholar]
  7. Bhattacharjee A. K., Jennings H. J., Kenny C. P., Martin A., Smith I. C. Structural determination of the sialic acid polysaccharide antigens of Neisseria meningitidis serogroups B and C with carbon 13 nuclear magnetic resonance. J Biol Chem. 1975 Mar 10;250(5):1926–1932. [PubMed] [Google Scholar]
  8. CURTIS S. N., KRAUSE R. M. ANTIGENIC RELATIONSHIPS BETWEEN GROUPS B AND G STREPTOCOCCI. J Exp Med. 1964 Oct 1;120:629–637. doi: 10.1084/jem.120.4.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Carey R. B., Eisenstein T. K., Shockman G. D., Greber T. F., Swenson R. M. Soluble group- and type-specific antigens from type III group B Streptococcus. Infect Immun. 1980 Apr;28(1):195–203. doi: 10.1128/iai.28.1.195-203.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Freimer E. H. Type-specific polysaccharide antigens of group B streptococci. II. The chemical basis for serological specificity of the type II HCl antigen. J Exp Med. 1967 Mar 1;125(3):381–392. doi: 10.1084/jem.125.3.381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hemming V. G., Hall R. T., Rhodes P. G., Shigeoka A. O., Hill H. R. Assessment of group B streptococcal opsonins in human and rabbit serum by neutrophil chemiluminescence. J Clin Invest. 1976 Dec;58(6):1379–1387. doi: 10.1172/JCI108593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Jennings H. J., Katzenellenbogen E., Lugowski C., Kasper D. L. Structure of native polysaccharide antigens of type Ia and type Ib group B Streptococcus. Biochemistry. 1983 Mar 1;22(5):1258–1264. doi: 10.1021/bi00274a042. [DOI] [PubMed] [Google Scholar]
  13. Jennings H. J., Lugowski C., Kasper D. L. Conformational aspects critical to the immunospecificity of the type III group B streptococcal polysaccharide. Biochemistry. 1981 Aug 4;20(16):4511–4518. doi: 10.1021/bi00519a001. [DOI] [PubMed] [Google Scholar]
  14. Jennings H. J., Rosell K. G., Kasper D. L. Structural determination and serology of the native polysaccharide antigen of type-III group B Streptococcus. Can J Biochem. 1980 Feb;58(2):112–120. doi: 10.1139/o80-016. [DOI] [PubMed] [Google Scholar]
  15. Jennings H. J., Rosell K. G., Kasper D. L. Structure and serology of the native polysaccharide antigen of type Ia group B streptococcus. Proc Natl Acad Sci U S A. 1980 May;77(5):2931–2935. doi: 10.1073/pnas.77.5.2931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Jennings H. J., Rosell K. G., Katzenellenbogen E., Kasper D. L. Structural determination of the capsular polysaccharide antigen of type II group B Streptococcus. J Biol Chem. 1983 Feb 10;258(3):1793–1798. [PubMed] [Google Scholar]
  17. Kane J. A., Karakawa W. W. Multiple polysaccharide antigens of group B streptococcus, type Ia: emphasis on a sialic acid type-specific polysaccharide. J Immunol. 1977 Jun;118(6):2155–2160. [PubMed] [Google Scholar]
  18. Kasper D. L., Baker C. J., Baltimore R. S., Crabb J. H., Schiffman G., Jennings H. J. Immunodeterminant specificity of human immunity to type III group B streptococcus. J Exp Med. 1979 Feb 1;149(2):327–339. doi: 10.1084/jem.149.2.327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kasper D. L., Goroff D. K., Baker C. J. Immunochemical characterization of native polysaccharides from group B streptococcus: the relationship of the type III and group B determinants. J Immunol. 1978 Sep;121(3):1096–1105. [PubMed] [Google Scholar]
  20. Lancefield R. C., Freimer E. H. Type-specific polysaccharide antigens of group B streptococci. J Hyg (Lond) 1966 Jun;64(2):191–203. doi: 10.1017/s0022172400040456. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Lancefield R. C., McCarty M., Everly W. N. Multiple mouse-protective antibodies directed against group B streptococci. Special reference to antibodies effective against protein antigens. J Exp Med. 1975 Jul 1;142(1):165–179. doi: 10.1084/jem.142.1.165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. McCARTY M., LANCEFIELD R. C. Variation in the group-specific carbohydrate of group A streptococci. I. Immunochemical studies on the carbohydrates of variant strains. J Exp Med. 1955 Jul 1;102(1):11–28. doi: 10.1084/jem.102.1.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. OUCHTERLONY O. Diffusion-in-gel methods for immunological analysis. Prog Allergy. 1958;5:1–78. [PubMed] [Google Scholar]
  24. SCHEIDEGGER J. J. Une micro-méthode de l'immuno-electrophorèse. Int Arch Allergy Appl Immunol. 1955;7(2):103–110. [PubMed] [Google Scholar]
  25. Wilkinson H. W. Detection of group B streptococcal antibodies in human sera by radioimmunoassay: concentrations of type-specific antibodies in sera of adults and infants infected with group B streptococci. J Clin Microbiol. 1978 Feb;7(2):194–201. doi: 10.1128/jcm.7.2.194-201.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Wilkinson H. W., Facklam R. R., Wortham E. C. Distribution by serological type of group B streptococci isolated from a variety of clinical material over a five-year period (with special reference to neonatal sepsis and meningitis). Infect Immun. 1973 Aug;8(2):228–235. doi: 10.1128/iai.8.2.228-235.1973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Wong K. H., Barrera O., Sutton A., May J., Hochstein D. H., Robbins J. D., Robbins J. B., Parkman P. D., Seligmann E. B., Jr Standardization and control of meningococcal vaccines, group A and group C polysaccharides. J Biol Stand. 1977;5(3):197–215. doi: 10.1016/s0092-1157(77)80005-x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES